过去 90 天内没有内部人买入。最近一笔由 Driscoll Martin J 披露于 2019年11月14日。
F-star Therapeutics, Inc.：高管交易动态
本页追踪F-star Therapeutics, Inc.高管申报的每一笔交易（来源：SEC (Form 4)）。公司属于医疗与制药行业。过去十二个月内，F-star Therapeutics, Inc.没有任何高管发布申报。最近一份申报的日期是2023年3月9日。
回溯至覆盖起点2016年，高管共申报51笔买入和9笔卖出。
这些数据整理自监管申报（来源：SEC (Form 4)），仅描述高管的操作，并非投资推荐。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2021财年截至 2021年12月 · cache
- 25,539 股@ US$7.1245.3% 占其流量股票SEC:0000899243-23-007665:1
- 9,375 股@ US$7.128.1% 占其流量股票SEC:0000899243-23-007662:1
- 25,019 股@ US$7.1245.1% 占其流量股票SEC:0000899243-23-007670:1
- 6,328 股@ US$7.126.1% 占其流量股票SEC:0000899243-23-007657:1
- 73,959 股@ US$7.1217.4% 占其流量股票SEC:0000899243-23-007669:1
- 3,937 股@ US$7.1298.4% 占其流量股票SEC:0000899243-23-007660:0
- 347,578 股@ US$7.1298.8% 占其流量股票SEC:0000899243-23-007669:0
- 15,004 股@ US$7.12100.0% 占其流量股票SEC:0000899243-23-007663:0
- 4,385 股@ US$7.12100.0% 占其流量股票SEC:0000899243-23-007656:0
- 8,386 股@ US$7.12100.0% 占其流量股票SEC:0000899243-23-007654:0
- 97,547 股@ US$7.12100.0% 占其流量股票SEC:0000899243-23-007657:0
- 29,236 股@ US$7.1296.0% 占其流量股票SEC:0000899243-23-007670:0
- 105,088 股@ US$7.1298.8% 占其流量股票SEC:0000899243-23-007662:0
- 30,898 股@ US$7.12100.0% 占其流量股票SEC:0000899243-23-007665:0
- 3,937 股@ US$0.111.6% 占其流量股票SEC:0001209191-23-002542:0
- 76,619 股@ US$0.111.2% 占其流量股票SEC:0001209191-22-044006:0
- 260,977 股@ US$0.111.2% 占其流量股票SEC:0001209191-22-044007:0
- 25 股@ US$6.850.1% 占其流量股票SEC:0001209191-21-063046:1
- 39 股@ US$6.810.1% 占其流量股票SEC:0001209191-21-063046:0
- 64 股@ US$7.22560.2% 占其流量股票SEC:0001209191-21-059842:0
- 26,437 股0股票SEC:0001209191-21-053227:0
- 26,437 股0股票SEC:0001209191-21-053224:0
- 16,875 股0股票SEC:0001209191-21-053233:0
- 1,054 股@ US$8.433.7% 占其流量股票SEC:0001209191-21-045957:0
- 142,000 股0股票SEC:0001209191-21-006781:0
143 条申报中的 25 条
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. (ticker: FSTX) was a U.S.-incorporated biopharmaceutical company formerly listed on NASDAQ in the United States. The company was focused on next-generation oncology and immunotherapy, with a core strategy built around the discovery and development of bispecific antibodies. F-star’s proprietary mAb2 platform was designed to create highly differentiated antibody candidates with the potential to address difficult-to-treat cancers and other serious diseases. The company ultimately became part of invoX Pharma, a subsidiary of Sino Biopharmaceutical, following the completion of an all-cash acquisition in March 2023. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1566373/000095017022024526/R7.htm?utm_source=openai))
Historically, F-star traced its corporate evolution through a name change from Spring Bank to F-star Therapeutics, Inc. in 2020. Its scientific identity, however, was shaped over more than a decade of internal platform development. The company highlighted a highly experienced team, mainly based in Cambridge, United Kingdom, with deep expertise in antibody engineering, immunology, drug discovery, clinical development, and regulatory affairs. That transatlantic footprint gave F-star a hybrid profile: a U.S.-listed issuer with a significant European research and development base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1566373/000095017022024526/R7.htm?utm_source=openai))
展开全文收起
From a business-line perspective, F-star was not a diversified biotech. It was a focused clinical-stage company centered on bispecific antibody programs in immuno-oncology. Its lead assets were being studied in Phase 2 trials in Europe and the United States, including in PD-1 acquired resistant head and neck cancer, checkpoint-inhibitor-naïve non-small cell lung cancer, and diffuse large B-cell lymphoma. The company positioned these programs as potentially first-in-class or best-in-class therapies aimed at unmet medical needs, which placed it in a competitive segment populated by large pharmaceutical companies and specialty biotech peers pursuing similar mechanisms. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1566373/000119312523065369/d438759dex99a5n.htm?utm_source=openai))
F-star’s competitive value proposition rested on technology differentiation rather than commercial scale. Its mAb2 platform and collaborations with partners such as Ares Trading, an affiliate of Merck KGaA, and Denali Therapeutics were intended to validate the platform and extend its scientific reach. In practical terms, the company’s presence was strongest in the U.K. for research activities, while its equity listing and corporate reporting were tied to the United States public markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1566373/000119312521030817/d123429dex993.htm?utm_source=openai))
The key recent event for investors is the company’s acquisition by invoX Pharma. The transaction was announced in June 2022, received the relevant regulatory clearances, including CFIUS review, and closed in March 2023 for approximately $161 million at $7.12 per share in cash. As a result, F-star is no longer an operating public standalone name, but its legacy SEC filings and insider transaction history remain relevant for historical analysis of FSTX. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1566373/000119312523065369/d438759dex99a5n.htm?utm_source=openai))
